Kairos Pharma Ltd. (NYSE American: KAPA) has released positive interim results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer, showing clinical benefit in 86% of treated patients. The findings, presented at the European Society for Medical Oncologists Meeting, indicate durable progression-free survival with no dose-limiting toxicities observed in the study population.
The clinical-stage biopharmaceutical company detailed these developments in a Letter to Shareholders from CEO John Yu, M.D., which outlined 2025 accomplishments and the outlook for 2026. The combination therapy's strong performance suggests ENV105 may extend the effectiveness of standard care while maintaining excellent tolerability, addressing a critical need in cancer treatment where drug resistance often limits therapeutic options.
ENV105 represents an innovative approach to cancer therapeutics, targeting CD105 - a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy frequently results in resistance and disease relapse. The antibody aims to reverse this drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types.
Kairos continues patient recruitment for the Phase 2 trial, with enrollment expected to reach 100 participants across leading U.S. cancer centers. The ongoing study focuses on castrate-resistant prostate cancer, while ENV105 is also being evaluated in a Phase 1 trial for lung cancer, addressing significant unmet medical needs in both indications.
The positive safety profile observed in the interim analysis is particularly significant given that combination therapies often introduce additional toxicity concerns. The absence of dose-limiting toxicities suggests ENV105 could be safely combined with existing standard treatments without compromising patient quality of life, potentially creating new treatment paradigms for advanced cancer patients who have developed resistance to conventional therapies.
For investors and stakeholders seeking additional information, the company maintains updated news and developments at https://ibn.fm/KAPA. The progress in ENV105 development represents an important advancement in the field of oncology therapeutics, particularly for patients with advanced metastatic prostate cancer who have limited treatment options once resistance develops to standard care regimens.
